1,852 research outputs found
The Cadet, 1916-09, vol. 03
No full textThe Cadet was published between 1914-1924 as an enterprise for the benefit of the Catholic Cadet Corps. A non-political publication, it covers a wide range of subjects of general interest, including the activities not only of the C.C.C., but of other Newfoundland cadet corps as well.Editorial -- Newfoundland and war / H. W. LeMessurier -- Eccentric persons : anecdotes of misers / A. S. R. -- Our great national industry / J. M. Devine -- Their names shall live in history -- Memoirs of Mrs. Grundy / Aguecheek -- Hobbies / Arch G. Gibb -- Where no man works -- The great conflict / Fred B. Wood -- The Irish in Newfoundland in the 19th Century, article XI : Hon. Moses Monroe / P. K. Devine -- A suggestion / R. T. McGrath -- Food and personality / by an M.D. -- A costly game / Eureka.Frequency: quarterly (?). Includes numerous advertisements
Transcranial direct current stimulation over right dorsolateral prefrontal cortex enhances error awareness in older age
No full textThe ability to detect errors during cognitive performance is compromised in older age and in a range of clinical populations. This study was designed to assess the effects of transcranial direct current stimulation (tDCS) on error awareness in healthy older human adults. tDCS was applied over DLPFC while subjects performed a computerized test of error awareness. The influence of current polarity (anodal vs cathodal) and electrode location (left vs right hemisphere) was tested in a series of separate single-blind, Sham-controlled crossover trials, each including 24 healthy older adults (age 65–86 years). Anodal tDCS over right DLPFC was associated with a significant increase in the proportion of performance errors that were consciously detected, and this result was recapitulated in a separate replication experiment. No such improvements were observed when the homologous contralateral area was stimulated. The present study provides novel evidence for a causal role of right DLPFC regions in subserving error awareness and marks an important step toward developing tDCS as a tool for remediating the performance-monitoring deficits that afflict a broad range of populations
The Cadet, 1918-09, vol. 05, no. 03
No full textThe Cadet was published between 1914-1924 as an enterprise for the benefit of the Catholic Cadet Corps. A non-political publication, it covers a wide range of subjects of general interest, including the activities not only of the C.C.C., but of other Newfoundland cadet corps as well.The defection of Bulgaria -- Kaiser squirming -- Austria-Hungary -- The new German Chancellor -- To the Germans : “U.S.” stands for unconditional surrender -- Is Newfoundland discovered? / J. M. Devine -- Laws and lawyers / A. S. R. -- Minister of Militia Bennett decorating soldier in France [illustration] -- Royal Newfoundland Regiment in France, inspected by Minister of Militia Bennett [illustration] -- Capt. V. S. Bennett ; Lieut. R. G. Reid [illustrations] -- Capt. Ronald Ayre [illustration] -- The world war year by year / H. B. -- The first set of fours / J. S. -- Sergt. F. J. Ricketts ; Corpl. Lawrence Clare [illustrations] -- Lieut.-Col A. E. Bernard [illustration] -- Diagnosis proves the value of a system -- How much can Canada stand? / N. H. -- Pte. William Carew ; Capt. B. Butler [illustrations] -- Sergt. T. J. Kean ; Sergt. A. R. Clouston [illustrations] -- Initiative or obedience -- A lawyer says so -- Just a snap in France ; Pte. T. Murphy [illustrations] -- C.Q.M.S. Ralph Andrews ; Pte. Edgar Whitten [illustrations] -- What Verdi said of the Germans -- The first day at school / John J. Cornwall -- What France did in the war -- Trooper Winsor ; Pte. W. Roost [illustrations] -- The Shamrocks of the Nineties, article II / Chas. E. Hunt -- Corpl. A. S. Cook ; Pte. Wm. Ebsary [illustrations] -- The Vatican and the Allies, article I -- Pte. Samuel Learning ; Pte. J. Dennihy [illustrations] -- Pte. J. J. Peddle ; Pte. Herbert N. Ebsary [illustrations] -- Ptes. Geo. and Stan. Abbott ; Pte. G. England [illustrations] -- What is a business man? -- We are proud of them -- Hon. Sir M. P. Cashin, K. B. E., Minister of Finance and Acting Premier -- No sympathy for sawdust / Ray De Luce -- Trooper R. Thistle ; Pte. John Spratt [illustrations] -- To our mothers!Frequency: quarterly (?). Includes numerous advertisements
Devine Intervention
No full textA 30 yo woman presented to the comprehensive ophthalmology clinic with bilateral decreased vision. She had no prior ocular history. Her medical history was notable for breast cancer (diagnosed 1 year prior), treated with radiation, chemotherapy, lumpectomy, and pembrolizumab (completed 8/9 planned infusions). She described progressive vision loss in both eyes over the 2 weeks with light sensitivity, pain with eye movements, and diminished color vision. Her best corrected visual acuity was 20/500 in the right eye and count fingers at 3\u27 in the left eye. No APD. Confrontation visual fields were notable for dense constriction in the right eye and temporal field loss in the left eye. The dilated funduscopic exam was normal. She was sent to the emergency department for an expedited work-up. MRI brain and orbits with and without contrast revealed T2 signal and enhancement along the optic chiasm, tracts, and prechiasmatic optic nerves (radiology images 1-4 ). There was no evidence of demyelinating lesions. Lumbar puncture and CT chest/abdomen/pelvis were unremarkable with no metastatic or systemic inflammatory process identified. A diagnostic procedure was performed.Hirano, S., Kojima, A., Nakayama, Y., Takeda, T., Kishimoto, T., Takahashi, T., Kuwabara, S., & Mori, M. (2022). A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: A clinical and immunohistochemical study. BMC Neurology, 22(1). https://doi.org/10.1186/s12883-022-02987-6, Nasralla, S., & Abboud, H. (2020). Is neuromyelitis optica without AQP4-IGG a T-cell-mediated disease? insights from checkpoint inhibitor immune-related adverse events. Multiple Sclerosis and Related Disorders, 46, 102451. https://doi.org/10.1016/j.msard.2020.102451, Wilson, R., Menassa, D. A., Davies, A. J., Michael, S., Hester, J., Kuker, W., Collins, G. P., Cossins, J., Beeson, D., Steven, N., Maddison, P., Rinaldi, S., Jacob, S., & Irani, S. R. (2018). Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Annals of Clinical and Translational Neurology, 5(5), 640-645. https://doi.org/10.1002/acn3.547. Vargas Pivato de Almeida, D. (2022). Neurological toxic effects associated with treatment with immune checkpoint inhibitors-are we really safer now? JAMA Network Open, 5(4). https://doi.org/10.1001/jamanetworkopen.2022.7731 Wingerchuk DM;Banwell B;Bennett JL;Cabre P;Carroll W;Chitnis T;de Seze J;Fujihara K;Greenberg B;Jacob A;Jarius S;Lana-Peixoto M;Levy M;Simon JH;Tenembaum S;Traboulsee AL;Waters P;Wellik KE;Weinshenker BG; ; (n.d.). International consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders. Neurology. https://pubmed.ncbi.nlm.nih.gov/26092914/ Yu, C. W., Yau, M., Mezey, N., Joarder, I., & Micieli, J. A. (2020, November 3). Neuro-ophthalmic complications of immune checkpoint inhibitors: A systematic review. Eye and brain. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648547/ Carrillo, P., Gorría, T., Santana, D., Sepulveda, M., Aldecoa, I., Gonzalez-Farré, B., Sanfeliu, E., Mension, E., Cebrecos, I., Martínez-Saez, O., Alonso, I., & Saiz, A. (2022). Aquaporin-4-positive triple-negative breast cancer presenting with paraneoplastic neuromyelitis Optica Spectrum disorder. Biomedicine Hub, 7(1), 11-16. https://doi.org/10.1159/000521578 Haanen J;Obeid M;Spain L;Carbonnel F;Wang Y;Robert C;Lyon AR;Wick W;Kostine M;Peters S;Jordan K;Larkin J; ; (n.d.). Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. https://pubmed.ncbi.nlm.nih.gov/36270461/ Daetwyler, E., Zippelius, A., Meyer, P., & Läubli, H. (2023). Pembrolizumabinduced optic neuropathy - A case report. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.117198
Devine Intervention
No full textA 30 yo woman presented to the comprehensive ophthalmology clinic with bilateral decreased vision. She had no prior ocular history. Her medical history was notable for breast cancer (diagnosed 1 year prior), treated with radiation, chemotherapy, lumpectomy, and pembrolizumab (completed 8/9 planned infusions). She described progressive vision loss in both eyes over the 2 weeks with light sensitivity, pain with eye movements, and diminished color vision. Her best corrected visual acuity was 20/500 in the right eye and count fingers at 3\u27 in the left eye. No APD. Confrontation visual fields were notable for dense constriction in the right eye and temporal field loss in the left eye. The dilated funduscopic exam was normal. She was sent to the emergency department for an expedited work-up. MRI brain and orbits with and without contrast revealed T2 signal and enhancement along the optic chiasm, tracts, and prechiasmatic optic nerves (radiology images 1-4 ). There was no evidence of demyelinating lesions. Lumbar puncture and CT chest/abdomen/pelvis were unremarkable with no metastatic or systemic inflammatory process identified. A diagnostic procedure was performed.Hirano, S., Kojima, A., Nakayama, Y., Takeda, T., Kishimoto, T., Takahashi, T., Kuwabara, S., & Mori, M. (2022). A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: A clinical and immunohistochemical study. BMC Neurology, 22(1). https://doi.org/10.1186/s12883-022-02987-6, Nasralla, S., & Abboud, H. (2020). Is neuromyelitis optica without AQP4-IGG a T-cell-mediated disease? insights from checkpoint inhibitor immune-related adverse events. Multiple Sclerosis and Related Disorders, 46, 102451. https://doi.org/10.1016/j.msard.2020.102451, Wilson, R., Menassa, D. A., Davies, A. J., Michael, S., Hester, J., Kuker, W., Collins, G. P., Cossins, J., Beeson, D., Steven, N., Maddison, P., Rinaldi, S., Jacob, S., & Irani, S. R. (2018). Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Annals of Clinical and Translational Neurology, 5(5), 640-645. https://doi.org/10.1002/acn3.547. Vargas Pivato de Almeida, D. (2022). Neurological toxic effects associated with treatment with immune checkpoint inhibitors-are we really safer now? JAMA Network Open, 5(4). https://doi.org/10.1001/jamanetworkopen.2022.7731 Wingerchuk DM;Banwell B;Bennett JL;Cabre P;Carroll W;Chitnis T;de Seze J;Fujihara K;Greenberg B;Jacob A;Jarius S;Lana-Peixoto M;Levy M;Simon JH;Tenembaum S;Traboulsee AL;Waters P;Wellik KE;Weinshenker BG; ; (n.d.). International consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders. Neurology. https://pubmed.ncbi.nlm.nih.gov/26092914/ Yu, C. W., Yau, M., Mezey, N., Joarder, I., & Micieli, J. A. (2020, November 3). Neuro-ophthalmic complications of immune checkpoint inhibitors: A systematic review. Eye and brain. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648547/ Carrillo, P., Gorría, T., Santana, D., Sepulveda, M., Aldecoa, I., Gonzalez-Farré, B., Sanfeliu, E., Mension, E., Cebrecos, I., Martínez-Saez, O., Alonso, I., & Saiz, A. (2022). Aquaporin-4-positive triple-negative breast cancer presenting with paraneoplastic neuromyelitis Optica Spectrum disorder. Biomedicine Hub, 7(1), 11-16. https://doi.org/10.1159/000521578 Haanen J;Obeid M;Spain L;Carbonnel F;Wang Y;Robert C;Lyon AR;Wick W;Kostine M;Peters S;Jordan K;Larkin J; ; (n.d.). Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. https://pubmed.ncbi.nlm.nih.gov/36270461/ Daetwyler, E., Zippelius, A., Meyer, P., & Läubli, H. (2023). Pembrolizumabinduced optic neuropathy - A case report. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.117198
Devine Intervention
No full textA 30 yo woman presented to the comprehensive ophthalmology clinic with bilateral decreased vision. She had no prior ocular history. Her medical history was notable for breast cancer (diagnosed 1 year prior), treated with radiation, chemotherapy, lumpectomy, and pembrolizumab (completed 8/9 planned infusions). She described progressive vision loss in both eyes over the 2 weeks with light sensitivity, pain with eye movements, and diminished color vision. Her best corrected visual acuity was 20/500 in the right eye and count fingers at 3\u27 in the left eye. No APD. Confrontation visual fields were notable for dense constriction in the right eye and temporal field loss in the left eye. The dilated funduscopic exam was normal. She was sent to the emergency department for an expedited work-up. MRI brain and orbits with and without contrast revealed T2 signal and enhancement along the optic chiasm, tracts, and prechiasmatic optic nerves (radiology images 1-4 ). There was no evidence of demyelinating lesions. Lumbar puncture and CT chest/abdomen/pelvis were unremarkable with no metastatic or systemic inflammatory process identified. A diagnostic procedure was performed.Hirano, S., Kojima, A., Nakayama, Y., Takeda, T., Kishimoto, T., Takahashi, T., Kuwabara, S., & Mori, M. (2022). A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: A clinical and immunohistochemical study. BMC Neurology, 22(1). https://doi.org/10.1186/s12883-022-02987-6, Nasralla, S., & Abboud, H. (2020). Is neuromyelitis optica without AQP4-IGG a T-cell-mediated disease? insights from checkpoint inhibitor immune-related adverse events. Multiple Sclerosis and Related Disorders, 46, 102451. https://doi.org/10.1016/j.msard.2020.102451, Wilson, R., Menassa, D. A., Davies, A. J., Michael, S., Hester, J., Kuker, W., Collins, G. P., Cossins, J., Beeson, D., Steven, N., Maddison, P., Rinaldi, S., Jacob, S., & Irani, S. R. (2018). Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Annals of Clinical and Translational Neurology, 5(5), 640-645. https://doi.org/10.1002/acn3.547. Vargas Pivato de Almeida, D. (2022). Neurological toxic effects associated with treatment with immune checkpoint inhibitors-are we really safer now? JAMA Network Open, 5(4). https://doi.org/10.1001/jamanetworkopen.2022.7731 Wingerchuk DM;Banwell B;Bennett JL;Cabre P;Carroll W;Chitnis T;de Seze J;Fujihara K;Greenberg B;Jacob A;Jarius S;Lana-Peixoto M;Levy M;Simon JH;Tenembaum S;Traboulsee AL;Waters P;Wellik KE;Weinshenker BG; ; (n.d.). International consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders. Neurology. https://pubmed.ncbi.nlm.nih.gov/26092914/ Yu, C. W., Yau, M., Mezey, N., Joarder, I., & Micieli, J. A. (2020, November 3). Neuro-ophthalmic complications of immune checkpoint inhibitors: A systematic review. Eye and brain. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648547/ Carrillo, P., Gorría, T., Santana, D., Sepulveda, M., Aldecoa, I., Gonzalez-Farré, B., Sanfeliu, E., Mension, E., Cebrecos, I., Martínez-Saez, O., Alonso, I., & Saiz, A. (2022). Aquaporin-4-positive triple-negative breast cancer presenting with paraneoplastic neuromyelitis Optica Spectrum disorder. Biomedicine Hub, 7(1), 11-16. https://doi.org/10.1159/000521578 Haanen J;Obeid M;Spain L;Carbonnel F;Wang Y;Robert C;Lyon AR;Wick W;Kostine M;Peters S;Jordan K;Larkin J; ; (n.d.). Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. https://pubmed.ncbi.nlm.nih.gov/36270461/ Daetwyler, E., Zippelius, A., Meyer, P., & Läubli, H. (2023). Pembrolizumabinduced optic neuropathy - A case report. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.117198
Safety Profile of Good Manufacturing Practice Manufactured Interferon γ-Primed Mesenchymal Stem/Stromal Cells for Clinical Trials
No full textMesenchymal stem/stromal cells (MSCs) are widely studied by both academia and industry for a broad array of clinical indications. The collective body of data provides compelling evidence of the clinical safety of MSC therapy. However, generally accepted proof of therapeutic efficacy has not yet been reported. In an effort to generate a more effective therapeutic cell product, investigators are focused on modifying MSC processing protocols to enhance the intrinsic biologic activity. Here, we report a Good Manufacturing Practice-compliant two-step MSC manufacturing protocol to generate MSCs or interferon γ (IFNγ) primed MSCs which allows freshly expanded cells to be infused in patients on a predetermined schedule. This protocol eliminates the need to infuse cryopreserved, just thawed cells which may reduce the immune modulatory activity. Moreover, using (IFNγ) as a prototypic cytokine, we demonstrate the feasibility of priming the cells with any biologic agent. We then characterized MSCs and IFNγ primed MSCs prepared with our protocol, by karyotype, in vitro potential for malignant transformation, biodistribution, effect on engraftment of transplanted hematopoietic cells, and in vivo toxicity in immune deficient mice including a complete post-mortem examination. We found no evidence of toxicity attributable to the MSC or IFNγ primed MSCs. Our data suggest that the clinical risk of infusing MSCs or IFNγ primed MSCs produced by our two-step protocol is not greater than MSCs currently in practice. While actual proof of safety requires phase I clinical trials, our data support the use of either cell product in new clinical studies
Patterns of Discovery
No full textFrom a given directed weighted network of knowledge links between technology fields, the paper develops a multisector dynamic model of incremental innovation and R&D activity in these fields. The model is focused on the equilibrium share distribution of these variables, which is proved to be locally stable, with reference to a simple low dimensional case. Simulation methods suggest that local, and also global, stability extend to any model dimension. It is also shown how different network structures map to different asymptotic share distributions. Using the NBER patents and patent citation data files, the analytical framework is then used to analyse some general features of the pattern of knowledge creation and transfer in the period 1975-1999. From a descriptive viewpoint, the changes in the share distribution of innovation activity predicted by the model match reasonably well the actual changes in the perioddirected weighted network, knowledge spillovers, share distribution, incremental innovation and R&D dynamics, local stability, simulation, patents and patent citations
The Pittsburgh district civic frontage.
No full textAt head of title: Russell Sage foundation.I. The community: Pittsburgh the year of the survey, by E. T. Devine. Pittsburgh: an interpretation of its growth, by R. A. Woods. Coalition of Pittsburgh's civic forces, by A. T. Burns.--II. Civic conditions: Civic improvement possibilities in Pittsburgh, by C. M. Robinson. Thirty-five years of typhoid, by F. E. Wing. The housing of Pittsburgh's workers, by Emily W. Dinwiddie and F. Elisabeth Crowell. Three studies in housing and responsibility: Skunk hollow, by Florence L. Lattimore. Painter's row, Tammany hall, by F. Elisabeth Crowell. The aldermen and their courts, by H. V. Blaxter and A. H. Kerr. The disproportion of taxation in Pittsburgh, by S. M. Harrison.--III. Children and the city: Pittsburgh schools, by Lila Ver P. North. The playgrounds of Pittsburgh, by Beulah Kennard. The public library, by Frances J. Olcott. Pittsburgh as a foster mother, by Florence L. Lattimore.--Appendices.Mode of access: Internet
Effective Autodissemination of Pyriproxyfen to Breeding Sites by the Exophilic Malaria Vector Anopheles Arabiensis in Semi-Field Settings in Tanzania.
No full text\ud
\ud
Malaria vector control strategies that target adult female mosquitoes are challenged by the emergence of insecticide resistance and behavioural resilience. Conventional larviciding is restricted by high operational costs and inadequate knowledge of mosquito-breeding habitats in rural settings that might be overcome by the juvenile hormone analogue, Pyriproxyfen (PPF). This study assessed the potential for Anopheles arabiensis to pick up and transfer lethal doses of PPF from contamination sites to their breeding habitats (i.e. autodissemination of PPF). A semi-field system (SFS) with four identical separate chambers was used to evaluate PPF-treated clay pots for delivering PPF to resting adult female mosquitoes for subsequent autodissemination to artificial breeding habitats within the chambers. In each chamber, a tethered cow provided blood meals to laboratory-reared, unfed female An. arabiensis released in the SFS. In PPF-treated chambers, clay pot linings were dusted with 0.2 - 0.3 g AI PPF per pot. Pupae were removed from the artificial habitats daily, and emergence rates calculated. Impact of PPF on emergence was determined by comparing treatment with an appropriate control group. Mean (95%CI) adult emergence rates were (0.21 +/- 0.299) and (0.95 +/- 0.39) from PPF-treated and controls respectively (p < 0.0001). Laboratory bioassay of water samples from artificial habitats in these experiments resulted in significantly lower emergence rates in treated chambers (0.16 +/- 0.23) compared to controls 0.97 +/- 0.05) (p < 0.0001). In experiments where no mosquitoes introduced, there were no significant differences between control and treatment, indicating that transfer of PPF to breeding sites only occurred when mosquitoes were present; i.e. that autodissemination had occurred. Treatment of a single clay pot reduced adult emergence in six habitats to (0.34 +/- 0.13) compared to (0.98 +/- 0.02) in the controls (p < 0.0001), showing a high level of habitats coverage amplification of the autodissemination event. The study provides proof of principle for the autodissemination of PPF to breeding habitats by malaria vectors. These findings highlight the potential for this technique for outdoor control of malaria vectors and call for the testing of this technique in field trials.\u
- …
